ProKidney (PROK) CLO Todd Girolamo Buys 163,857 Shares

Todd Girolamo, the Chief Legal Officer of PROK, recently acquired 163,857 shares of the company on June 12, 2026. The purchase was not part of a pre-planned trading program, suggesting a personal decision to increase his stake in the company.

Insider Buying and Selling at ProKidney Corp.

On June 12, 2026, Todd Girolamo, the Chief Legal Officer, made a significant purchase of 163,857 shares of PROK. This transaction was not under a Rule 10b5-1 trading plan. Other recent insider activities include purchases by William Doyle, Uma Sinha, and Alan Lotvin, each acquiring 135,000 shares on May 28, 2026.

Other Institutional Activity in PROK

Institutional investors have been active in PROK as well. Morgan Stanley increased its holdings by 138,966 shares, reaching a total of 8,955,967 shares valued at approximately $16.03 million. Millennium Management LLC added 437,041 shares, bringing its stake to 2,271,577 shares worth about $4.07 million. Meanwhile, Artia Global Partners LP reduced its position by 31,472 shares, resulting in a total of 1,806,939 shares valued at $3.23 million.

ProKidney Corp. Stock Down 12.6%

Shares of PROK are currently trading at $1.67. The stock has attracted attention with a variety of institutional and insider activities. Despite the current trading price, analysts have set higher price targets, reflecting potential future growth.

Analysts Set New Price Targets

On May 18, 2026, HC Wainwright & Co. reiterated a buy rating for PROK, maintaining a price target of $12. Other firms like UBS and Guggenheim have maintained buy ratings with targets of $8 and $7, respectively. However, B of A Securities downgraded the stock to a sell with a target of $1 on June 30, 2025. The consensus among analysts is generally positive, with a mean target price reflecting optimism about the stock's potential.

Bottom Line

The recent insider purchase by Todd Girolamo adds an interesting layer to the ongoing activities surrounding PROK, suggesting confidence in the company's future. Institutional movements and analyst ratings further highlight the stock's potential. As always, it's important for investors to consider these backward-looking insights from 13F filings and insider activities as part of a larger investment strategy.